Connect with us

Trending

Anti-COVID-19 drug was first studied by Patanjali, claims Acharya Balkrishna

Published

on

Anti-COVID-19 drug was first studied by Patanjali, claims Acharya Balkrishna
0 0
Read Time:1 Minute, 1 Second

The anti-COVID-19 drug developed by DRDO (Defence Research and Development Organization) named 2-deoxy-D-glucose which has been given the permission to be used in emergency by DCGI was first studied by Patanjali researchers, claimed Acharya Balkrishna.

On Sunday, a day after the drug was granted permission, Balkrishna tweeted, “We take immense pride that Patanjali has been the pioneer centre-stone for most of the researches conducted for COVID-19.” 

On Patanjali studied

He tweeted this with a picture of his research paper, co-authored with 3 other researchers. On this, Swami Ramdev said, “Proud of Patanjali being the first in every research on COVID-19.”

Anti-COVID-19 drug was first studied by Patanjali, claims Acharya Balkrishna
Image Source- Google } Image By- Hindustan Times

This drug is developed by INMAS in collaboration with DRL. In the first wave of covid, INMAS-DRDO scientists conducted experiements with CCMB’s help in which they discovered that this molecule works against the Coronavirus and stops its growth. Based on that, they were permitted for a Phase-2 trial.

Phase-2 trial was conducted on 110 patients and it took about 6 months in which the drug was found to be safe on COVID-19 patients.

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Continue Reading
Click to comment

Average Rating

5 Star
0%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Leave a Reply

Your email address will not be published. Required fields are marked *